The latest version of the Parkinson’s Hope List is now available at https://t.co/MXVxXMBq9W . It has 237 projects in Research stage, 98 in Discovery and 139 in Pre-clinical; and 166 in Clinical stage broken down by phase. #Parkinsons 1/2

"The start of recruitment to the EJS ACT-PD trial offers real hope to people living with Parkinson's and their families.” Helen Matthews, CEO, Cure Parkinson’s. Learn how this new project will help transform Parkinson’s clinical trials in the UK: https://t.co/Wa9jgRfYVT

We’re excited to announce that recruitment for the first multi-arm, multi-stage (MAMS) platform for Parkinson’s in the UK – @EJS_ACT_PD – is open. This project will continuously test new therapies that could impact Parkinson's progression: https://t.co/O3M15zbf2P #ejsactpd

Remember kids: "Pathology does not mean disease. Most individuals with pathology will never have disease" Wonderful letter from @AlbertoEspay & @ajlees! "In the reality we inhabit, we have made Lewy pathology not just a marker of PD, but its very maker! https://t.co/bGniZz8OJ0

Honored to be asked to contribute to the Parky Charter effort by the wonderful Movers & Shakers @moversand6 - the Quest for a Cure (for #Parkinsons) https://t.co/XVpmT7a7c4

What medicines do people with Parkinson's want? @touteiro , Carmo Bastos and I try to answer the question in @journal_PD #Parkinsons . It's #openaccess as well. https://t.co/wKOaRp0cRB

Coincidentally in today’s Guardian -

“As such, moderation in the communication of prognosis and of the potential of new medicines is essential, so that PwP can maintain hope rather than being misled by hype.” in ⁦@journal_PD⁩

The Parkinson's Foundation has launched PD Trial Navigator to help increase enrollment in clinical studies testing gene-targeted therapies. https://t.co/0bvi86aYQn

Press summary associated with this research: https://t.co/RR08tPGSvl

Replenishing the brain’s natural stores of lithium can protect against and even reverse Alzheimer’s disease https://t.co/Z4sUteT7jD

Sumitomo Pharma apply for marketing authorisation of a stem cell replacement therapy for Parkinson's

Could gene therapy silence Parkinson’s progression? A study in primates just showed it may be possible. Steece-Collier and colleagues knocked it out of the park in their new paper in Molecular Therapy. The group studied aged macaques and demonstrated that targeting CaV1.3

Shades of grey: The continuum of therapies for Parkinson's disease along the spectrum of credibility - Araceli Alonso-Canovas, Olaf M Dekkers, Bas Bloem, 2025p

Unmet needs in the pharmacological management of motor symptoms in Parkinson's disease - Beatrice Heim, Werner Poewe, 2025

What are the FDA approved drugs for non-motor and neuropsychiatric symptoms in Parkinson's? We need to do better and this needs to be part of the plan. https://t.co/HgZNvTKZHu Thanks Jen Goldman for updating us on this 'lack of progress.' Let's do better as people are counting on

Can specialized physical therapy help you to live longer with Parkinson’s? What if physical therapy did more than improve balance and reduce falls? A new Dutch study by Ypinga, Bloem and colleagues just dropped and the results are fascinating. Specialized physical therapy, like

Dopamine acts like a laser pointer and not a sprinkler. Dopamine isn’t just about pleasure or motion, it’s about precision coding at the cellular level. Maybe we should stop stereotyping dopamine as a simple splashy brain signal. An interesting new study in Science by Yee, Ford

Wow! Big data dump: @_neuroproteome presents 250M protein measurements from >35K biofluid samples (plasma, serum & cerebrospinal fluid) contributed by 23 partners, spanning #Alzheimers, #Parkinsons, frontotemporal dementia & #ALS; Biomarker discovery https://t.co/UT2Yg30L67

It’s not just tremors in Parkinson's, we need to broaden our rehabilitation lens beyond balance and gait. We need rehabilitation strategies for sleep and autonomic symptoms like constipation, urinary and sexual dysfunction. We’ve long focused on movement, but what about the

Pharmather eyes commercialization of Parkinson’s ketamine drug